Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 2/20 | 0.53 |
| ▸ | CTSK | P43235 | 2/20 | 0.53 |
| ▸ | REN | P00797 | 15/20 | 0.51 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | CTSD | P07339 | 1/20 | 0.45 |
| ▸ | CTSE | P14091 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8536013 | 0.93 | CTSS (0.56) | CTSSCTSKRENCA1CA2 | |
| SCHEMBL6448979 | 0.93 | CTSS (0.56) | CTSSCTSKRENCA1CA2 | |
| SCHEMBL9848334 | 0.93 | CTSS (0.56) | CTSSCTSKRENCA1CA2 | |
| SCHEMBL8269723 | 0.92 | CTSK (0.55) | CTSSCTSKRENCA1CA2 | |
| SCHEMBL12631616 | 0.92 | CTSK (0.55) | CTSSCTSKRENCA1CA2 | |
| SCHEMBL7265417 | 0.91 | CTSS (0.52) | CTSSCTSKRENCA1CA2 | |
| SCHEMBL7272524 | 0.90 | CTSS (0.51) | CTSSCTSKRENCA1CA2 | |
| SCHEMBL7272530 | 0.90 | CTSS (0.51) | CTSSCTSKRENCA1CA2 | |
| SCHEMBL7284721 | 0.89 | CTSS (0.55) | CTSSCTSKRENCA1CA2 | |
| SCHEMBL7297295 | 0.88 | CTSS (0.52) | CTSSCTSKRENCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050080141-A1 | Amino diols useful in the treatment of alzheimer's disease | SCHOSTAREZ HEINRICH J (US) | 2005-04-14 | — | — | US | claimed |
| EP-1712227-A1 | Amino diols useful in the treatment of Alzheimer's disease | Elan Pharmaceuticals, Inc. (US) | 2006-10-18 | — | — | EP | disclosed |
| US-20050080141-A1 | Amino diols useful in the treatment of alzheimer's disease | SCHOSTAREZ HEINRICH J (US) | 2005-04-14 | — | — | US | disclosed |
| US-4977141-A | RENIN INHIBITORS | G. D. SEARLE & CO. (US) | 1990-12-11 | — | — | US | disclosed |
| EP-0310071-A2 | Non-peptidyl alpha-aminoacyl aminodiol carbamates as anti-hypertensive agents | G.D. Searle & Co. (US) | 1989-04-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080141-A1 | Amino diols useful in the treatment of alzheimer's disease | BACE1, BACE2, APP | CTSS 127/4885CTSK 551/4885REN 2199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.